Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. reduced its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 20.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 45,094 shares of the specialty pharmaceutical company’s stock after selling 11,400 shares during the period. John G Ullman & Associates Inc.’s holdings in Jazz Pharmaceuticals were worth $5,024,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 116 shares during the last quarter. Arizona State Retirement System raised its holdings in Jazz Pharmaceuticals by 0.8% in the second quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock valued at $1,770,000 after buying an additional 130 shares during the period. Cardinal Capital Management raised its position in Jazz Pharmaceuticals by 1.9% in the second quarter. Cardinal Capital Management now owns 12,068 shares of the specialty pharmaceutical company’s stock valued at $1,288,000 after purchasing an additional 227 shares during the period. Finally, Waterfront Wealth Inc. lifted its position in shares of Jazz Pharmaceuticals by 2.5% during the second quarter. Waterfront Wealth Inc. now owns 9,411 shares of the specialty pharmaceutical company’s stock worth $1,004,000 after purchasing an additional 230 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. This represents a 8.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,110 shares of company stock worth $720,160 in the last three months. 4.20% of the stock is owned by insiders.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $119.24 on Thursday. The stock has a fifty day moving average price of $112.64 and a 200 day moving average price of $110.45. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17. The stock has a market cap of $7.21 billion, a price-to-earnings ratio of 16.79, a PEG ratio of 0.98 and a beta of 0.57.

Analysts Set New Price Targets

Several brokerages have issued reports on JAZZ. Cantor Fitzgerald restated an “overweight” rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. HC Wainwright reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Royal Bank of Canada increased their target price on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research note on Wednesday, October 23rd. Finally, Wells Fargo & Company reduced their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $175.53.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.